Finance

Beta
Lists
NTRA:NASDAQ
Natera Inc
$234.76
+2.60%
(+5.96) 1D
$235.06
+0.13% (+0.30)
After hours
Closed: Jun 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTRA...
Open
$225.71
High
$240.72
Low
$224.35
Mkt. cap
33.62B
Avg. vol.
1.57M
Volume
0.00
52-wk high
$256.27
52-wk low
$131.81
EPS
-$1.64
Beta
1.56
Shares outstanding
143.22M
No. of employees
6K
Open
$225.71
High
$240.72
Low
$224.35
Mkt. cap
33.62B
Avg. vol.
1.57M
Volume
0.00
52-wk high
$256.27
52-wk low
$131.81
EPS
-$1.64
Beta
1.56
Shares outstanding
143.22M
No. of employees
6K
News stories
From sources across the web
Profile
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
About Natera Inc
CEOSteven Chapman
Employees6.14K
FoundedJan 1, 2004
HeadquartersAustin, Texas, United States
SectorBiotechnology
Websitenatera.com
Analyst Ratings
Based on 16 analysts giving stock ratings to NTRA in the past 3 months
Strong Buy
Buy
14
Hold
2
Sell
0
12 month forecast
Based on 16 Wall Street analysts offering 12 month price targets for NTRA in the last 3 months.
Highest
Current $234.76
$300.00 (+27.79%)
Average
$265.29 (+13.00%)
Lowest
$220.00 (-6.29%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Mark Massaro
BTIG
Buy
Reiterated
$270.00
+15%
06/23/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
$285.00
+21.4%
06/23/2026
David Westenberg
Piper Sandler
Buy
Maintained
$249.00
+6.1%
06/23/2026
Puneet Souda
Leerink Partners
Buy
Maintained
-
-
06/22/2026
Dan Leonard
RBC Capital
Buy
Initiated
$275.00
+17.1%
06/11/2026
Evie Koslosky
Goldman Sachs
Hold
Initiated
$245.00
+4.4%
06/05/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
$260.00
+10.8%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
$260.00
+10.8%
06/01/2026
Patrick B Donnelly
Citi
Buy
Maintained
$300.00
+27.8%
05/28/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
$250.00
+6.5%
05/12/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
$270.00
+15%
05/08/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$265.00
+12.9%
05/08/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
$220.00
-6.3%
05/08/2026
Casey Woodring
J.P. Morgan
Buy
Reiterated
$265.00
+12.9%
05/08/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/08/2026
Luke Sergott
Barclays
Buy
Reiterated
$280.00
+19.3%
05/08/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$280.00
+19.3%
05/07/2026
William Bonello
Craig-Hallum
Buy
Maintained
$224.00
-4.6%
03/04/2026
Unknown Analyst
Jefferies
Buy
Reiterated
$275.00
+17.1%
02/27/2026
Subbu Nambi
Guggenheim
Buy
Reiterated
$270.00
+15%
02/26/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.60 / -$0.55
-8.52%miss
Revenue / Est. (USD)
696.64M / 617.07M
+12.90%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
546.60M
592.18M
665.50M
696.64M
Cost of goods sold
200.00M
207.80M
220.07M
245.81M
Cost of revenue
200.00M
207.80M
220.07M
245.81M
Research and development expenses
146.43M
173.41M
175.19M
210.70M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
310.55M
308.55M
291.30M
320.74M
Operating expense
456.98M
481.96M
468.21M
537.15M
Total operating expenses
656.97M
689.76M
688.28M
782.96M
Operating income
-110.37M
-97.58M
-22.78M
-86.32M
Other non operating income
-
-
-
-
EBT including unusual items
-100.66M
-87.34M
-13.33M
-84.81M
EBT excluding unusual items
-100.66M
-87.34M
-13.33M
-77.61M
Income tax expense
275.00K
207.00K
-60.58M
283.00K
Effective tax rate
-0.27%
-0.24%
454.63%
-0.33%
Other operating expenses
-
-
-
-
Net income
-100.94M
-87.54M
47.26M
-85.09M
Net profit margin
-18.47%
-14.78%
7.10%
-12.21%
Earnings per share
-0.74
-0.64
0.36
-0.60
Interest and investment income
10.74M
11.28M
10.45M
9.60M
Interest expense
-1.03M
-1.04M
-991.00K
-892.00K
Net interest expenses
9.71M
10.24M
9.46M
8.71M
Depreciation and amortization charges
-
-
-
-
EBITDA
-100.51M
-87.28M
-13.69M
-66.09M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer